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Cervical cancer is the third most common cancer afflicting women, 
with an estimated 530 000 new cases and 275 000 deaths each year 
(1).  Cervical  cancer  incidence  and  mortality  rates  in  developed 
countries have declined via cervical cytology screening campaigns 
(2). However, more than 85% of the global cervical cancer resides 
in less-developed countries (2), which generally lack the infrastructure 
to obtain and store cytology specimens and train cytopathologists 
to interpret these specimens. Different methods for cervical cancer 
screening in less-developed countries have been explored, of which 
the one that is most often recommended is visual inspection with 
acetic acid (VIA) (2).
As the world’s most populous country, with 70% of its popula-
tion living in rural areas, China accounts for 14% of the world’s 
annual incidence of cervical cancer (75 500 new cases) and 12% of 
the world’s annual mortality from cervical cancer (34 000 deaths) 
(1). Cervical cancer screening in China remains opportunistic and 
is based in cities, whereas rural areas in central China have the 
highest cervical cancer burden (3). In 2009, the Chinese govern-
ment launched a cervical cancer prevention program that aims to 
screen 10 million rural Chinese women using a Pap smear or VIA 
over a 3-year period (4). However, with an estimated 500 million 
women in rural areas, China lacks a sufficient number of cytopa-
thologists or trained health-care workers to screen all of these 
women by Pap smear or VIA, respectively.
Human papillomavirus (HPV) DNA testing has been proposed 
as an alternative to cytology for cervical cancer screening. Unlike 
VIA, HPV DNA testing provides highly sensitive, objective, and 
reliable results based on the presence of high-risk HPV DNA in 
cervicovaginal  samples  (5–9).  A  recent  pooled  analysis  study  in 
China  (10)  showed  HPV  DNA  testing  to  be  highly  accurate 
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 Background  Worldwide, one-seventh of cervical cancers occur in China, which lacks a national screening program. By evaluating 
the diagnostic accuracy of self-collected cervicovaginal specimens tested for human papillomavirus (HPV) DNA 
(Self-HPV testing) in China, we sought to determine whether Self-HPV testing may serve as a primary cervical 
cancer screening method in low-resource settings.
  Methods  We compiled individual patient data from five population-based cervical cancer–screening studies in China. 
Participants (n = 13 140) received Self-HPV testing, physician-collected cervical specimens for HPV testing 
(Physician-HPV testing), liquid-based cytology (LBC), and visual inspection with acetic acid (VIA). Screen-
positive women underwent colposcopy and confirmatory biopsy. We analyzed the accuracies of pooled Self-
HPV testing, Physician-HPV testing, VIA, and LBC to detect biopsy-confirmed cervical intraepithelial neoplasia 
grade 2 or more severe (CIN2+) and CIN3+. All statistical tests were two-sided.
  Results  Of 13 004 women included in the analysis, 507 (3.9%) were diagnosed as CIN2+, 273 (2.1%) as CIN3+, and 37 
(0.3%) with cervical cancer. Self-HPV testing had 86.2% sensitivity and 80.7% specificity for detecting CIN2+ and 
86.1% sensitivity and 79.5% specificity for detecting CIN3+. VIA had statistically significantly lower sensitivity for 
detecting CIN2+ (50.3%) and CIN3+ (55.7%) and higher specificity for detecting CIN2+ (87.4%) and CIN3+ (86.9%) 
(all P values < .001) than Self-HPV testing, LBC had lower sensitivity for detecting CIN2+ (80.7%, P = .015), similar 
sensitivity for detecting CIN3+ (89.0%, P = .341), and higher specificity for detecting CIN2+ (94.0%, P < .001) and 
CIN3+ (92.8%, P < .001) than Self-HPV testing. Physician-HPV testing was more sensitive for detecting CIN2+ 
(97.0%) and CIN3+ (97.8%) but similarly specific for detecting CIN2+ (82.7%) and CIN3+ (81.3%) (all P values 
<.001) than Self-HPV testing.
  Conclusions  The sensitivity of Self-HPV testing compared favorably with that of LBC and was superior to the sensitivity 
of VIA. Self-HPV testing may complement current screening programs by increasing population coverage in 
settings that do not have easy access to comprehensive cytology-based screening.
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compared with cytology and VIA and concluded that HPV DNA 
testing could become a primary screening test for the secondary 
prevention of cervical cancer in developing countries. Historically, 
HPV DNA has been obtained from cervical specimens collected by 
a health-care professional during a pelvic speculum examination at a 
health-care clinic. However, a recent meta-analysis (11) concluded 
that there was good to very good concordance between self- 
collected cervicovaginal specimens and physician-directed cervical 
specimens for HPV DNA detection. Many women may also prefer 
self-collection compared with physician collection (11–13). Unlike 
physician-collected specimens, self-collection does not require a 
speculum examination, health-care professionals or a visit to a clinic 
because women can self-collect a specimen at home. It may be more 
practical as an initial screen in low-resource settings. To our know-
ledge, no large studies exist that analyze the diagnostic accuracy 
of self-collection with HPV DNA testing (Self-HPV testing) for 
histologically confirmed cervical precancer and cancer as a primary 
screening test in developing countries.
To address this gap in knowledge, we performed a pooled analysis 
of data from more than 13 000 women from five population-based 
cervical cancer screening studies conducted in rural China. By 
comparing the diagnostic accuracy of Self-HPV testing with that 
of physician-collected specimens tested for HPV DNA (Physician-
HPV testing), VIA, and liquid-based cytology (LBC), we aim to 
define the role that Self-HPV testing may play in cervical cancer 
screening campaigns in China and other low-resource settings 
worldwide.
Subjects and Methods
The Cancer Institute and Hospital of the Chinese Academy of 
Medical Sciences (CICAMS, Beijing, China) and Cleveland Clinic 
(Cleveland, OH) screened women in population-based cross-sectional 
cervical cancer screening studies from 1999 to 2007. The Human 
Subjects  Review  Boards  of  CICAMS  and  Cleveland  Clinic   
approved these studies. Eligible women were sexually active, not 
pregnant, with an intact uterus, and had no history of cervical 
intraepithelial neoplasia grade 2 or more severe (CIN2+) disease or 
pelvic radiation. No women had been screened for cervical cancer 
for at least 5 years before enrollment, and all provided written 
informed consent. Women included in the pooled analysis all con-
currently received HPV DNA testing (Hybrid Capture 2 [HC2] 
assay; Qiagen, Gaithersburg, MD) for self-collected and physician-
obtained samples, LBC, and VIA. The study methods for each 
individual study have been outlined in detail elsewhere (3,14,15).
Study Populations
Our pooled analysis used individual patient data from five projects 
in  the  SPOCCS  (Shanxi  Province  Cervical  Cancer  Screening 
Study). Individual study details are shown in Table 1. SPOCCS I 
and II were conducted in Shanxi province (3,14), whereas SPOCCS 
III (three projects) extended to also include Xinjiang and Henan 
provinces (15). In SPOCCS I, all women received colposcopy and 
biopsy (3). In SPOCCS II and III, women who tested positive for 
HPV DNA or VIA or had LBC results of atypical squamous cell 
of undetermined significance (ASC-US) or more severe (ASC-US 
or more) received colposcopy and biopsy (14,15).
Screening Tests
HPV Testing.  HPV DNA testing was performed using the high-
risk probe of the HC2 test, which detects a pool of 13 high-risk 
HPV types (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, 
HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and HPV68). 
All women performed self-collection followed by physician-directed 
sampling  according  to  previously  described  protocols  (3,14,15). 
The majority (85.2%) of sample processing and laboratory testing 
was  performed  at  CICAMS  in  Beijing,  China.  For  primary 
analyses, HPV DNA positivity was defined according to the manu-
facturer’s  recommended  positive  cut  point  of  1.0  relative  light 
units per cutoff (1.0 RLU/CO; approximately equal to 1.0 pg 
DNA per mL), as was used in clinical studies for colposcopy 
referral (3,5).
Cytology and Visual Inspection.  All patients underwent LBC, 
and the results were graded according to the Bethesda system 
(16). Almost all studies had cytology read by cytopathologists at 
CICAMS in Beijing; the exception was SPOCCS III-Xinjiang, 
CONTEXTS AND CAVEATS
Prior knowledge
Liquid-based cytology (LBC), visual inspection with acetic acid (VIA), 
and human papillomavirus (HPV) DNA testing of cervical specimens 
(physician-collected cervical specimens for HPV testing [Physician-
HPV testing]) can be effective to screen for women at high risk for 
cervical cancer, but all of these methods require medical resources. 
The authors sought to determine whether HPV testing of self-
collection of cervical specimens (Self-HPV testing) could be an 
accurate screening method for women in low-resource settings.
Study design
More than 13 000 rural Chinese women received Self-HPV testing, 
Physician-HPV testing, LBC, and VIA. Screen-positive women received 
colposcopy and cervical biopsies. The accuracy of each screening 
method  to  detect  biopsy-confirmed  cervical  intraepithelial  neo-
plasia grade 2 or higher (CIN2+) was compared.
Contribution
There were 507 (3.9%) women diagnosed with CIN2+, 273 (2.1%) 
with CIN3+, and 37 (0.3%) with cervical cancer. Patient compli-
ance with Self-HPV testing was high. Self-HPV testing had 86.2% 
sensitivity and 80.7% specificity for detecting CIN2+ and 86.1% 
sensitivity  and  79.5%  specificity  for  detecting  CIN3+.  Self-HPV 
testing was more sensitive and less specific than VIA and LBC but 
less sensitive and similarly specific compared with Physician-HPV 
testing.
Implication
Self-HPV testing may be a more effective means than VIA or cytology 
to provide cervical cancer screening in low-resource settings.
Limitations
In this study, women were instructed by medical professionals on 
self-sampling procedures, and it remains to be seen whether unsu-
pervised self-sampling would give comparable outcomes. The cost 
and laboratory requirements of the HPV DNA assay might also be 
prohibitive in some settings.
From the Editors
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where cytology was read on-site by local pathologists and reviewed 
by senior cytopathologists at CICAMS. Unpublished internal analyses 
showed  the  sensitivity  and  specificity  of  SPOCCS  III-Xinjiang 
cytology to be comparable to those of other sites (data not shown). 
Trained Chinese gynecologists conducted VIA on all women.
Biopsy.  Women  who  were  positive  for  any  screening  test  in 
SPOCCS II and III and all women in SPOCCS I underwent 
colposcopy. Directed biopsy using a 2-mm brochoscopy biopsy 
instrument was taken from all visible cervical lesions. When the 
four-quadrant punch biopsy method was indicated (see Table 1), 
biopsies were taken at positions of 2, 4, 8, and 10 o’clock.
Verification of Disease Status.  This study combined individual 
data from five studies to estimate pooled sensitivity and specificity 
for the detection of histological CIN2+ and CIN3+. In most studies, 
cytology  and  biopsy  slides  were  read  at  CICAMS.  International 
pathology  experts  reviewed  14.8%  of  cytology  and  35.0%  of 
biopsy  results  and  independently  assessed  them  for  quality 
control.
To pool the data, we unified the criteria to verify disease status. 
The gold standard was histologically confirmed biopsy results. In 
our study population, the 7449 (56%) of 13 140 women who had 
no biopsy results, negative Physician-HPV tests, and negative or 
ASC-US results from LBC were considered to be disease free. 
This standard was based on findings from the SPOCCS I project 
that only one women with CIN2+ (1 [0.07%] of 1511 women, 95% 
confidence interval [CI] = 0.003% to 0.4%) and no women with 
CIN3+ (0 [0.0%] of 1511 women, 95% CI = 0.0% to 0.2%) were 
diagnosed among the group of women who had negative Physician-
HPV tests and negative or ASC-US results from LBC and had 
received colposcopy and biopsy (3). One woman who had no 
biopsy, negative cytology, a positive Physician-HPV test, and neg-
ative colposcopy was also categorized as disease negative. Women 
without biopsy results were considered to have incomplete results 
if they had the following test results and were therefore excluded 
from analysis: 1) 17 (0.1%) of 13 140 women with positive Pap 
tests that indicated presence of low-grade squamous intraepithelial 
lesion or more severe cytology; 2) seven (0.05%) of 13 140 women 
with ASC-US Pap tests and positive Physician-HPV tests, and 3) 
Table 1. Characteristics of pooled studies*
No Study name
Study year  
and location
Number  
screened Age (y) Screening tests Follow-up procedure
Histology or cytology   
location and review
1 SPOCCS I 1999; Xiangyuan  
  County, Shanxi  
  Province
1997 35–45 HC2 (self, physician),  
  fluorescence test,  
  LBC, VIA,  
  colposcopy
All women received  
  four-quadrant biopsies  
  and ECC under  
  colposcopy.
CICAMS; Blinded  
  International  
  Review
2 SPOCCS II 2001–2002; Xiangyuan  
  and Yangcheng  
  Counties, Shanxi  
  Province
8497 35–50 HC2 (self, physician),  
  LBC, VIA, AFB
Positive VIA, self-test  
  or physician-test for  
  high-risk HPV, or an  
  abnormal AFB, or a  
  positive Pap test (ASC–US  
  or worse): four-quadrant  
  biopsies and ECC.
CICAMS
3 SPOCCS III-(1) 2006; Xiangyuan  
  County, Shanxi  
  Province
884 16–54 HC2 (self, physician),  
  LBC, VIA
(1) Positive VIA or positive  
  self-collected HC2:  
  colposcopy and directed  
  biopsy, ECC if necessary;  
  (2) positive physician- 
  collected HC2 or ASC-H  
  and LSIL+ on LBC:  
  colposcopy and four- 
  quadrant biopsies, ECC if  
  necessary.
CICAMS; Blinded  
  International  
  Review (only  
  histology)
4 SPOCCS III-(2) 2006; Xinmi,  
  Henan Province
879 16–54 HC2 (self, physician),  
  LBC, VIA
Same as SPOCCS III-(1) CICAMS; Blinded  
  International  
  Review (only  
  histology)
5 SPOCCS III-(3) 2006; Yutian County,  
  Xinjiang Uygur  
  Autonomous  
  Region
883 16–54 HC2 (self, physician),  
  LBC, VIA
Same as SPOCCS III-(1) CICAMS; Blinded  
  International Review  
  (Histology); People’s  
  Hospital of Xinjiang  
  Uygur Autonomous  
  Region; Blinded  
  CICAMS Review  
  (Cytology)
Total   13 140      
*  AFB = Ampersand’s fluorescent bio-molecular markers; ASC-H = atypical squamous cells—cannot exclude high-grade squamous intraepithelial lesion; ASC-US = 
atypical squamous cell of undetermined significance; CICAMS = Cancer Institute of the Chinese Academy of Medical Sciences; ECC = endocervical curettage; 
HC2 = Hybrid Capture 2; HPV = human papillomavirus; LBC = liquid-based cytology; LSIL+ = low-grade squamous intraepithelial lesion or more severe; SPOCCS = 
Shanxi Province Cervical Cancer Screening Study; VIA = visual inspection with acetic acid.jnci.oxfordjournals.org    JNCI | Articles 181
27 (0.2%) of 13 140 women with positive Physician-HPV tests and 
negative cytology and missing or positive colposcopy.
Statistical Analysis
This pooled analysis presents the accuracy of Self-HPV testing, 
Physician-HPV  testing,  VIA,  and  LBC  to  detect  CIN2+  and 
CIN3+. To assess heterogeneity between studies, Q tests and I
2 
tests were used. If inter-study heterogeneity was not statistically 
significant, sensitivities and specificities were pooled by the fix-
effect model using the F distribution method. When inter-study 
heterogeneity was statistically significant, a random-effect model 
with  normal  approximation  was  used  to  correct  overdispersion. 
Sensitivities and specificities of these four screening methods were 
also calculated after stratifying the population by age (15–34, 35–
44, and ≥45 years).
Women without biopsy results—including 7450 screen-negative 
women and 51 screen-positive women—were stratified into sub-
groups according to Physician-HPV, LBC, colposcopy, Self-HPV, 
and VIA results to assess whether the established criteria for 
women without biopsy results affect the accuracy of screening 
tests. The estimated number of women with CIN2+ and CIN3+ 
who might have been missed in each subgroup was calculated using 
the probabilities of CIN2+ and CIN3+ generated from SPOCCS 
I data as the weights (in SPOCCS I, all women had biopsies). The 
corrected accuracy was computed with the estimated number of 
women with CIN2+ and CIN3+.
Forest plots were used to display the variations of sensitivities 
and specificities in Self-HPV testing among the individual studies 
and  pooled  analysis  measures.  Receiver  operating  characteristic 
(ROC) curves were created to compare the trade-offs in sensitivity 
and specificity with cutoff values of 1.0 and 2.0 pg/mL. The above 
pooled  analyses  on  the  accuracy  of  screening  methods  were 
performed using Meta-Disc 1.4 (Meta-analysis of Diagnostic and 
Screening Tests, Version 1.4) (17). The pooled positivity of screening 
methods was calculated with random-effect models.
Trends in screening method accuracy with age groups were 
calculated using the Cochran–Armitage trend test. McNemar tests 
were used to compare paired matching data like the sensitivities, 
specificities, and fraction of positive results between different tests 
or positive results between the 1.0 and 2.0 pg/mL cutoff values of 
the  Self-HPV  testing.  Continuous  variables  were  estimated  by 
calculating the means, medians, and standard deviations. These 
two  statistical  analyses  were  performed  using  SAS  9.1  (SAS 
Institute Inc, Cary, NC). All statistical tests were two-sided, with 
P values less than or equal to .05 considered to be statistically 
significant.
Results
In total, 13 140 rural Chinese women aged 17–56 years were screened 
using Self-HPV testing, VIA, Physician-HPV testing, and LBC. 
None of these women refused to perform self-collection. Of the 
13 140 women, eight (0.1%) had Self-HPV testing data missing, 71 
(0.5%) had Physician-HPV testing data missing, one (0.01%) had 
Self-HPV and Physician-HPV testing data missing, four (0.03%) 
had LBC data missing, and one (0.01%) had VIA data missing; all 
85 women with missing data were excluded (Figure 1). Exclusion 
of an additional 51 women with positive Pap or physician-HPV 
results, but no biopsy resulted in inclusion of 13 004 women in 
the final analysis. Of these, 5554 (42.7%) had diagnoses that were 
Figure 1. Flow chart of inclusion and exclusion 
criteria of the study sample. ASC-US = atypical 
squamous cell of undetermined significance; 
LBC = liquid-based cytology; LSIL+ = low-grade 
squamous intraepithelial lesion or more severe; 
HPV = human papillomavirus; Physician-HPV, 
physician-collected  cervical  specimens  for 
HPV testing; Self-HPV = self-collected cervi-
covaginal  specimens  tested  by  HPV  DNA 
testing; VIA = visual inspection with acetic 
acid.
13 140 women were screened in five 
population-based studies 
51 without biopsy were excluded, including 
seven ASC-US and positive Physician-HPV 
17 LSIL+ 
27 positive Physician-HPV, negative cytology, and 
missing/positive colposcopy results
13 004 were included in final analysis with biopsy 
confirmed or assumed final diagnosis 
5554 were confirmed   
by biopsy 
7449 deemed negative due to 
negative/ASC-US and 
negative Physician-HPV 
One deemed negative due to   
negative cytology, positive 
Physician-HPV, and negative colposcopy 
85 with missing screening results were excluded, including: 
eight missing Self-HPV,   
71 missing Physician-HPV,   
one missing Self-HPV and Physician-HPV, 
four missing cytology,   
one missing VIA
13 055 had Self-HPV, Physician-HPV, 
cytology, and VIA results182   Articles | JNCI  Vol. 104, Issue 3  |  February 8, 2012
confirmed by biopsy. Most women were 35–49 years old (11 140 
[85.7%]  of  13 004)  and  had  one  lifetime  sexual  partner  (9008 
[69.5%] of 12 967; 37 with missing data). Nearly all of the women 
were nonsmokers (12 556 [96.6%] of 12 997; seven with missing 
data) and married (12 772 [98.3%] of 12 999; five with missing 
data). Of 13 004 women included in the study, there were 234 
(1.8%) diagnosed as CIN2+, 236 (1.8%) as CIN3+, and 37 (0.3%) 
with cervical cancer.
Test Positivity
We examined the pooled data to determine the percentages of the 
13 004 women who tested positive for CIN1, CIN2, and CIN3+ 
diagnoses with Self-HPV testing, Physician-HPV testing, LBC, 
and VIA (Table 2). The overall test positivity of LBC (6.0%) was 
statistically  significantly  lower  than  that  of  the  other  testing 
modalities, which ranged from 14.7% for Physician-HPV testing 
to 16.4% for VIA (P < .001). Physician-HPV and Self-HPV testing 
showed good agreement for HPV testing results (k = 0.67 [95% 
CI = 0.52 to 0.79]; agreement rate = 91.8% [95% CI = 84.9% to 
95.7%]) with Self-HPV testing demonstrating greater overall test 
positivity than Physician-HPV testing (15.6% vs 14.7%; P < .001).
Test positivity increased in all screening methods with increasing 
severity of histopathologic diagnosis. Physician-HPV testing was 
the most accurate screening method for high-grade lesions (P < 
.001), detecting 95.4% of CIN2 and 97.8% of CIN3+. For CIN2 
diagnoses, Self-HPV testing was more likely to test positive than 
LBC (82.8% vs 72.1%; P < .001) but was similarly positive for 
those with CIN3+ diagnoses (86.1% vs 89.0%; P = .341). In com-
parison, VIA was the least sensitive screening method for identi-
fying women with CIN2 and CIN3+ diagnoses (49.3% and 55.7% 
positivity, respectively; both P < .001).
Sensitivity and Specificity of Screening Tests
We then compared the overall and age-stratified sensitivities and 
specificities of each testing method for CIN2+ and CIN3+ (Table 3). 
For Self-HPV testing, the pooled sensitivity was 86.2% for CIN2+ 
and  86.1%  for  CIN3+  (Figure  2).  The  pooled  sensitivity  for 
Physician-HPV testing was much higher for CIN2+ (97.0%) and 
CIN3+ (97.8%) (P values < .001), whereas that of LBC was lower 
for  CIN2+  (80.7%;  P  =  .015)  and  non-significantly  higher  for 
CIN3+ (89.0%; P = .341). There was no statistically significant 
variation between age groups in the sensitivities of Self-HPV 
testing, Physician-HPV testing, and LBC for detecting CIN2+ or 
CIN3+ lesions. Conversely, the pooled sensitivity of VIA was not 
only statistically significantly lower than that of Self-HPV testing 
for detecting CIN2+ (50.3% vs 86.2%) and CIN3+ (55.7% vs 
86.1%) (P values were <.001), but it also decreased statistically 
significantly in older age groups. For example, the sensitivity of 
VIA to detect CIN3+ lesions deceased from 75.0% in women aged 
younger than 35 years to 48.4% in women aged 45 years or older 
(Ptrend = .054).
Pooled  specificity  of  Self-HPV  was  the  lowest  of  all  testing 
methods for both less than CIN2 (80.7%) and less than CIN3 
(79.5%) (P values were <.001) (Figure 2); furthermore, Self-HPV 
specificity varied statistically significantly with age, with the highest 
specificity in women aged younger than 35 years and the lowest in 
women aged 35–44 years for less than CIN2 (Ptrend < .001) and less 
than CIN3 (Ptrend < .001). Pooled specificities of Physician-HPV 
testing had a similar trend. Comparatively, the pooled specificity 
of VIA for less than CIN2 (87.4%) and for less than CIN3 (86.9%) 
increased with age (Ptrend < .001) and peaked in women aged 45 
years or older. The pooled specificity of LBC was the highest of all 
testing methods for less than CIN2 (94.0%) and less than CIN3 
(92.8%) (P values < .001) and varied with age for less than CIN2 
(Ptrend = .028) and less than CIN3 (Ptrend = .011).
We calculated the corrected accuracy of each screening test for 
CIN2+  and  CIN3+  using  results  from  SPOCCS  I  as  weighted 
controls because women without biopsies in SPOCCS II and III 
were assumed to be negative or incomplete in uncorrected speci-
ficity and sensitivity (Table 4). This statistical analysis detected an 
additional seven CIN2+ and one CIN3+ lesions, of which five 
instances of CIN2+ and no instances of CIN3+ were diagnosed in 
women who were previously categorized as negative. The remain-
ders  were  from  women  with  incomplete  results.  Because  no 
screening test had any statistically significant variation between 
uncorrected and corrected sensitivities and specificities, we focused 
our data analysis on the uncorrected values. A further sensitivity 
analysis including the 51 women in the negative biopsy group 
found no impact on sensitivities and specificities of all tests (data 
not shown).
We also calculated the sensitivity and specificity for combined 
screening strategies that used Self-HPV testing as a primary screen. 
The first combination was for Self-HPV testing–positive women 
who were referred for follow-up cytology screening. Compared 
with that of Self-HPV testing or cytology as stand-alone tests, the 
sensitivity of Self-HPV testing with cytology triage was lower for 
CIN2+ (71.2% [95% CI = 67.0% to 75.1%]; P < .001) and CIN3+ 
(77.7% [95% CI = 72.2% to 82.5%]; P < .001). Conversely, the 
Table 2. Pooled data on percentage of women testing positive with Self-HPV, Physician-HPV, LBC, and VIA by the grade of histopathology 
(HPV DNA positivity: RLU/CO ≥ 1 pg/mL)*
Grade of 
histopathology No. of women Self-HPV, % (95% CI)
Physician-HPV,  
% (95% CI) LBC, % (95% CI) VIA, % (95% CI)
Normal 11 935 10.8 (6.7 to 17.0) 9.3 (6.0 to 14.1) 2.5 (1.6 to 3.9) 13.9 (6.8 to 26.2)
CIN1 562 80.1 (61.0 to 91.1) 80.4 (62.9 to 90.8) 40.3 (28.9 to 52.9) 33.3 (21.7 to 47.3)
CIN2 234 82.8 (72.0 to 90.0) 95.4 (91.7 to 97.5) 72.1 (60.8 to 81.2) 49.3 (35.8 to 63.0)
CIN3+ 273 86.1 (81.4 to 90.0) 97.8 (95.3 to 99.2) 89.0 (84.7 to 92.5) 55.7 (45.1 to 66.3)
Total 13 004 15.6 (10.7 to 22.3) 14.7 (10.4 to 20.3) 6.0 (4.1 to 8.8) 16.4 (8.8 to 28.3)
*  CI = confidence interval; CIN1 = cervical intraepithelial neoplasia grade 1; CIN2 = cervical intraepithelial neoplasia grade 2; CIN3+ = cervical intraepithelial 
neoplasia grade 3 or more severe; HPV = human papillomavirus; LBC = liquid-based cytology; RLU/CO = relative light units per cutoff; VIA = visual inspection 
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specificity of the combined screening strategy was increased for 
CIN2+ (95.9% [95% CI = 94.9% to 96.9%]; P < .001) and CIN3+ 
(94.8% [95% CI = 93.5% to 96.1%]; P < .001). The colposcopy 
referral rate for Self-HPV testing with cytology would be 4.8% 
(95% CI = 3.3% to 6.7%). If Self-HPV testing–positive women 
were referred for VIA, the sensitivity decreased statistically signif-
icantly to 46.2% (95% CI = 37.7% to 54.6%; P < .001) for CIN2+ 
and to 51.3% (95% CI = 41.8% to 60.8%; P < .001) for CIN3+. 
Specificity increased to 97.1% (95% CI = 96.2% to 98.0%; P < 
.001) for CIN2+ and 96.4% (95% CI = 95.4% to 97.5%) for 
CIN3+. The colposcopy referral rate for this combined strategy 
would be 4.5% (95% CI = 3.3% to 6.1%).
RLU/CO for Positivity
Increasing cutoffs for Self-HPV test positivity from the standard 
1.0 to 2.0 pg/mL decreased the overall test positivity from 15.6% 
(95% CI = 10.7% to 22.3%) to 13.0% (95% CI = 8.9% to 18.7%) 
(P < .001). Increasing to 2.0 pg/mL only slightly decreased pooled 
sensitivity  from  86.2%  (95%  CI  =  82.9%  to  89.1%)  to  83.2% 
(95% CI = 79.7% to 86.4%) (P < .001) and increased specificity 
from 80.7% (95% CI = 75.6% to 85.8%) to 84.0% (95% CI = 
79.7% to 88.3%) (P < .001) for CIN2+ (Figure 3). Similar patterns 
were  observed  for  CIN3+  sensitivity  (from  86.1%  [95%  CI  = 
81.4% to 90.0%] to 84.2% [95% CI = 79.4% to 88.4%]; P = .06) 
and specificity (from 79.5% [95% CI = 74.1 to 84.8%] to 82.8% 
Figure 2. Forest plots of pooled and indi-
vidual study sensitivities and specificities 
of self-collected cervicovaginal specimens 
tested by HPV DNA testing (Self-HPV) for the 
detection of CIN2+ (A) and CIN3+ (B) (HPV 
DNA positivity: RLU/CO ≥ 1 pg/mL). The point 
estimate of each study was represented by a 
square,  whose  size  corresponded  to  the 
weight of the study in the pooled analysis. 
A horizontal line represents the 95% confi-
dence  interval.  The  overall  estimate  was 
presented at the bottom of the forest plots, 
represented as a diamond. Two vertical lines 
around the diamond represent the confidence 
interval of the overall estimate. CI = confidence 
interval; CIN2+ = cervical intraepithelial neo-
plasia  grade  2  or  more  severe;  CIN3+  = 
cervical  intraepithelial  neoplasia  grade  3 
or more severe; HPV = human papilloma-
virus; RLU/CO = relative light units per cutoff; 
SPOCCS = Shanxi Province Cervical Cancer 
Screening Study.jnci.oxfordjournals.org    JNCI | Articles 185
[95% CI = 78.2% to 87.3%]; P < .001). In other words, changing the 
cut point from 1.0 to 2.0 would decrease the sensitivity of CIN2+ and 
CIN3+ by 3% and 1.9%, respectively, while increasing the specificity 
of both CIN2+ and CIN3+ by 3.3%. Thus, if the elevated cut point 
were applied to the age-standardized female population in China, 
there would be 72 fewer CIN2+ diagnoses per 100 000 women or 25 
fewer CIN3+ diagnoses per 100 000 women, but false-positive tests 
would decrease by 3221 per 100 000 women with less than CIN2 or 
by 3257 per 100 000 women with less than CIN3.
Discussion
This pooled analysis from China is the largest study worldwide, to 
our knowledge, to examine the diagnostic accuracy of Self-HPV 
Table 4. Uncorrected and corrected HC2 accuracy of Self-HPV, Physician-HPV, LBC and VIA for CIN2+ and CIN3+ (HPV DNA positivity: 
RLU/CO ≥ 1 pg/mL)*
Screening methods
CIN2+ CIN3+
Sensitivity, %, (95% CI) Specificity, %, (95% CI) Sensitivity, %, (95% CI) Specificity, %, (95% CI)
Self-HPV      
  Uncorrected 86.2 (82.9 to 89.1) 80.7 (75.6 to 85.8) 86.1 (81.4 to 90.0) 79.5 (74.1 to 84.8)
  Corrected 85.0 (81.6 to 88.0) 80.8 (80.1 to 81.4) 85.8 (81.1 to 89.7) 79.5 (78.8 to 80.2)
  Difference 1.2 20.1 0.3 0.0
Physician-HPV      
  Uncorrected 97.0 (95.2 to 98.3) 82.7 (78.4 to 87.0) 97.8 (95.3 to 99.2) 81.3 (76.7 to 85.8)
  Corrected 96.1 (94.1 to 97.6) 82.5 (81.8 to 83.2) 97.8 (95.3 to 99.2) 81.1 (80.4 to 81.7)
  Difference 0.9 0.2 0.0 0.2
LBC      
  Uncorrected 80.7 (77.0 to 84.0) 94.0 (92.2 to 95.8) 89.0 (84.7 to 92.5) 92.8 (90.6 to 94.9)
  Corrected 80.0 (75.8 to 83.0) 93.9 (93.4 to 94.3) 88.8 (84.3 to 92.2) 92.7 (92.2 to 93.1)
  Difference 0.7 0.1 0.2 0.1
VIA      
  Uncorrected 50.3 (40.9 to 59.7) 87.4 (79.5 to 95.4) 55.7 (45.1 to 66.3) 86.9 (78.9 to 94.8)
  Corrected 49.6 (45.2 to 54.0) 87.5 (86.9 to 88.0) 55.6 (49.6 to 61.7) 86.9 (86.3 to 87.5)
  Difference 0.7 20.1 0.1 0.0
*  CI = confidence interval; CIN2+ = cervical intraepithelial neoplasia grade 2 or more severe; CIN3+ = cervical intraepithelial neoplasia grade 3 or more severe; LBC = 
liquid-based cytology; HC2 = Hybrid Capture 2; HPV = human papillomavirus; RLU/CO = relative light units per cutoff; VIA = visual inspection with acetic acid.
Figure 3. ROC curves of self-collected cervicovaginal specimens tested 
by HPV DNA testing (Self-HPV) for the detection of CIN2+ and CIN3+. 
Solid lines represent detection of CIN2+; dotted lines represent de-
tection of CIN3+. CIN2+ = cervical intraepithelial neoplasia grade 2 or 
more severe; CIN3+ = cervical intraepithelial neoplasia grade 3 or 
more severe; HPV = human papillomavirus; ROC = receiver operating 
characteristic.
testing as a primary screening tool for CIN2+ and CIN3+ detec-
tion. Data were generated in rural women from a less-developed 
country, where comprehensive cervical cytology screening cam-
paigns are difficult to establish and maintain. Our findings indicate 
that Self-HPV testing is more sensitive, though less specific, than 
LBC or VIA and that the sensitivity and specificity of Self-HPV 
testing moderately agrees with those of Physician-HPV testing.
The  pooled  Self-HPV  sensitivity  for  CIN2+  in  this  study 
(86.2%) was higher than the sensitivities reported for population-
based studies of Self-HPV testing in South Africa (66%) (18) and 
the Americas (49%) (19), but similar to those from the United 
Kingdom (81%) (20), in a referral population from India (83%) 
(21), and in young women from the United States (85%) (22). 
Discrepancies in observed test sensitivity between studies may be 
because of differences in sampling methods, population character-
istics, diagnostic ascertainment or criteria, or disease burden. 
Our results were consistent with some previous reports that Self-
HPV testing has a lower sensitivity than Physician-HPV testing 
(11,21,22),  but  not  others  (19,23).  The  sensitivity  of  Self-HPV 
testing may be lower than that of Physician-HPV testing because 
self-collected samples are less likely to sample cervical lesions (15). 
The lower specificity of Self-HPV testing is likely because of the 
common presence of vaginal HPV (24–26) that is not necessarily 
associated with CIN2+ (15).
Our finding that Self-HPV testing is more sensitive but less 
specific than cytology is consistent with previous studies (5,14,21,22). 
The specificity of HPV DNA testing decreases with age in our 
study population, similar to previous reports in China (10), but 
unlike prior studies in the United States, which show increasing 
HPV DNA specificity with age (5). This disparity likely relates to 
varying patterns of HPV prevalence in these two countries: HPV 
prevalence peaks in young- and middle-aged women in China (10) 
but peaks only in young women in the United States (5). Of note, 
our cytology results are more sensitive than those previously 
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most  of  slides  were  reviewed  by  expert  cytopathologists  from 
CICAMS instead of local pathologists. The costs of LBC and 
the requirement of qualified cytopathologists may prohibit its 
use as a screening test without a concomitant increase in CIN2+ 
detection (28).
One strength of this pooled analysis was that nearly half of the 
women, any with a positive screening testing, received colposcopy 
and  diagnostic  biopsy,  including  four-quadrant  punch  biopsies 
when no suspicious lesion was observed in colposcopy (29). Thus, 
disease misclassification was minimized (30). Another strength was 
that the population-based study design determined the feasibility 
of conducting Self-HPV testing in rural China. Approximately 
70% of invited women agreed to participate, and no participants 
refused to perform self-collection. Almost all women (99.9%) pro-
vided a sufficient self-collected sample, consistent with previous 
studies  that  found  Self-HPV  testing  to  be  a  satisfactory  initial 
screening method for screened women (12,31,32) as well as for 
nonattendees of European Pap smear programs (13).
One limitation in our study is that medical professionals instructed 
participants  on  self-sampling  procedures  in  clinics.  To  include 
women without health-care access, Self-HPV screening campaigns 
should also offer to deliver self-sampling kits with straightforward 
instructions to women’s homes for unsupervised specimen collec-
tion  and  should  then  refer  HPV-positive  women  for  further 
management. One study of women living in India concluded that 
unsupervised collection was impractical because many participants 
provided inadequate samples (21). However, studies from Western 
Europe mailed self-collection kits with instructional pamphlets to 
participants’ homes and reported near-perfect specimen collection 
(33) with 90% adherence to follow-up for women with positive 
HPV results from self-collection (13). More research is needed 
to determine an educational intervention that can be sent with 
self-collection  kits  to  ensure  that  unsupervised  women  from 
low-resource settings will provide adequate samples for HPV 
DNA testing.
The World Health Organization recommends VIA as a primary 
screening method in developing countries (2), and a cluster ran-
domized controlled trial in India found VIA to be a technically 
undemanding, inexpensive screen-and-treat intervention for cer-
vical cancer (34). However, our results have shown that Self-HPV 
testing is statistically significantly more effective than VIA at detecting 
CIN2+ and CIN3+ lesions, supporting previous research (35). We 
also have demonstrated that Self-HPV testing, unlike VIA, pro-
vides age-independent sensitivity. A recent study of women living 
in Tanzania showed that VIA positivity peaks immediately after 
training and retraining (36), suggesting that the sensitivity of VIA 
may be practitioner and training dependent. Self-HPV testing 
provides objective results independent of physician training and 
women’s ages and therefore may prove to be more sustainable 
than VIA in countries with limited resources for cervical cancer 
screening.
The HC2 assay’s expense, duration of testing, and laboratory 
requirements may potentially impede the large-scale incorporation 
of Self-HPV testing in the screening campaigns of low-resource 
countries (5,37,38). However, a new portable HPV DNA test, 
care HPV, provides results within 2.5 hours and costs one-tenth as 
much as HC2. Results from care HPV testing were found to be 
comparable to HC2 in sensitivity, specificity, and positive vs neg-
ative  predictive  values,  even  though  careHPV  testing  was  con-
ducted  in  suboptimal  laboratory  conditions  (39).  Self-collection 
with careHPV testing may provide the most viable primary screening 
option in low-resource settings.
Although developed countries use cytology-based cervical can-
cer screening programs, most developing countries lack a sufficient 
number of cytopathologists, gynecologists, and medical facilities to 
support comprehensive cytology screening (2). In these settings, 
Self-HPV testing could serve as a primary screening test and use 
of the more specific tests, cytology or HPV genotyping, could be 
reserved for women who have tested positive by Self-HPV testing 
and require further management. As shown in this study, cytology 
could be reserved for the 15% of Chinese women whose Self-HPV 
testing was positive, allowing the limited number of cytopatholo-
gists to focus on high-risk women. Although this study did not 
directly evaluate a strategy of screening women with Self-HPV 
testing and triage of positives by cytology, our statistical simulation 
of this algorithm projected a substantially lower colposcopy referral 
rate and a moderate loss of sensitivity compared with Self-HPV 
testing alone, in accordance with previous research (22). We also 
simulated the performance of VIA on Self-HPV testing–positive 
women, which substantially improves specificity but worsens sensi-
tivity. This strategy may be beneficial to one-visit screen-and-treat 
programs in low-resource settings that wish to minimize overtreat-
ment. More research is needed not only to determine how to imple-
ment effective Self-HPV testing screening programs but also to 
determine how to optimize the management of women with positive 
HPV test results, particularly in low-resource settings (40).
There are important programmatic implications of our study 
regarding  the  accuracy  of  HPV  DNA  testing  on  self-collected 
cervical specimens. A computer-based modeling study (38) showed 
that it was cost-effective in resource-poor settings, compared with 
conventional three-visit cytology-based screening, to screen women 
once in their lifetime between the ages of 35 and 45 years with one 
or two clinical visits strategies involving VIA or DNA testing for 
HPV in cervical cell samples. The most cost-effective strategies 
were those that required the fewest visits. Visual inspection of the 
cervix requires a pelvic examination with a sterile speculum, and 
cytology and Physician-HPV testing also require medical profes-
sionals  to  be  present  to  obtain  the  cervical  samples.  Although 
China historically has used minimally trained “barefoot doctors” 
to provide basic medical care in rural areas, health-care reforms in 
the 1980s drastically decreased federal funding for barefoot doc-
tors, causing a severe reduction of medical providers and public 
health efforts in rural China (41). Primary health care is a key and 
central component of China’s health-care reform program, which 
was announced in 2009 (42). However, many critical challenges, 
including the lack of qualified personnel, need to be overcome to 
rebuild a comprehensive health-care system in China. Furthermore, 
the most medically underserved Chinese women live in remote or 
mountainous areas with limited access to health care. Thus, even 
though we found that Physician-HPV testing is more sensitive 
than Self-HPV testing and others have shown that Self-HPV 
testing followed by cytology is more cost-effective than Self-HPV 
testing alone (22), the current shortage of adequately trained 
medical professionals in China renders the establishment of a jnci.oxfordjournals.org    JNCI | Articles 187
comprehensive physician-dependent cervical cancer screening 
program  infeasible.  Although  it  is  not  specific  enough  to  be  a 
stand-alone test, Self-HPV testing provides sensitive results with-
out pelvic exams, medical professionals, or health-care facilities 
and thus has the potential to serve as a primary cervical cancer 
screening  method  for  women,  regardless  of  their  geographic 
location or access to health care. Limited resources can then be 
focused on the clinical follow-up of the smaller percentage of 
women  who  tested  positive.  The  incorporation  of  Self-HPV 
testing  in  the  Chinese  government’s  ongoing  cervical  cancer 
screening  program  would  complement  the  current  program  by 
increasing its coverage of unscreened populations, particularly the 
large number of geographically isolated Chinese women.
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